Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $6.88 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.